Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in adults with psoriasis
IRCT20240420061533N1Phase 4Completed
- Sponsor
- Cobel Darou
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apremilast in psoriasis, sponsored by Cobel Darou. Primary endpoints: Occurrence of serious adverse events, Psoriasis Area and Severity Index (PASI) and 2 more. Started May 2025; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20240420061533N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240420061533N1.